Skip to content

The Clinical study of endoscopic surgery combined with platelet-rich plasma (PRP) for lumbar disc herniation

the Clinical study of endoscopic surgery combined with platelet-rich plasma (PRP) for lumbar disc herniation

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039100
Enrollment
Unknown
Registered
2020-10-17
Start date
2020-10-24
Completion date
Unknown
Last updated
2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Disc Herniation

Interventions

Control Group:Endoscopic surgery

Sponsors

The Ninth People's Hospital Affiliated to Medical College of Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Young and middle-aged patients aged 20-60 years old; 2. Patients with severe lumbocrural pain, recurrent attacks, ineffective after more than 3 months of non-surgical treatment, affecting work or life; 3. For patients with herniation of nucleus pulposus, L3-L4, L4-L5 and L5-S1 were the single responsible segments, and the imaging evidence was consistent with clinical symptoms and signs; 4. Patients with Pfirrmann grade II-IV judged by MRI T2 weighted images; 5. Patients who need endoscopic surgery conditions; 6. Patients who voluntarily participate in the trial are willing to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with vertebral segment instability such as spondylolisthesis requiring fusion; 2. Patients with unexplained back pain or non root leg pain; 3. Patients with lumbosacral cone damage caused by tumor, trauma, tuberculosis and various infectious and metabolic diseases; 4. Patients with poor general condition and severe impairment of heart, lung, brain, kidney and other important organs and hematopoietic function; 5. Patients with systemic or local active infection; 6. Patients with mental and neurological disorders who cannot cooperate with treatment; 7. Patients who have recently received radiotherapy, chemotherapy, immunosuppressant and anticoagulant therapy; 8. Patients with allergic constitution or allergic to materials and reagents related to disease treatment; 9. Pregnant and lactating women; 10. Patients who participated in other clinical trials in recent 3 months.

Design outcomes

Primary

MeasureTime frame
ODI score;Incidence of symptomatic reherniation;Complications;Surgical data;

Secondary

MeasureTime frame
VAS score;Pfirrmann grade;

Countries

China

Contacts

Public ContactYouzhuan Xie

The Ninth People's Hospital Affiliated to Medical College of Shanghai Jiaotong University

phoque711@163.com+86 18019790719

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026